Maha Katabi, Sofinnova general partner (Photo: Sofinnova website)
February 16, 2024 11:20 AM EST
People
Financing
Startups

Sofinno­va’s Ma­ha Katabi on re­cent M&A and IPO suc­cess and how deal flow has ‘nev­er been any bet­ter’

Kyle LaHucik

Senior Reporter

Ma­ha Katabi has had a great three months. The Sofinno­va gen­er­al part­ner has been in the board­room of two re­cent M&A ex­its: ra­dio­phar­ma­ceu­ti­cals mak­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

A service from the Financial Times